Neurodegenerative Disease Therapeutics Industry Data Book Covers Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market. The global neurodegenerative disease industry combine to account for USD 8.33 billion revenue in 2021, which is expected to reach USD 28.15 billion by 2030, growing at a cumulative rate of 15.6% over the forecast period. Grand View Research’s neurodegenerative disease therapeutics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview. Parkinson’s Disease Treatment Market Insights The global Parkinson’s disease treatment market size was valued at USD 4.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. The increasing geriatric population, which is exposed to a high risk of developing Parkinson’s Disease (PD), the high burden of PD in western countries, and the strong product pipeline of disease-modifying therapies are anticipated to be major drivers for the industry. According to the International Parkinson and Movement Disorder Society, in 2020, around 9.4 million individuals had PD worldwide. Moreover, PD affects around 1% of the total population over the age of 60 years, which rises to 5% for the population over the age of 85 years. North America dominated the global industry with a maximum revenue share of 37.90% in 2021. This dominance can be attributed to the presence of leading players in the region, such as AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC., and Sunovion Pharmaceuticals Inc. These players support growth by introducing new PD symptom management products. For instance, in May 2020, the U.S. FDA approved Kynmobi developed by Sunovion Pharmaceuticals Inc., to treat off-episodes in patients with PD. Furthermore, extensive research in the field of PD in the region is anticipated to positively contribute to the market growth. Alzheimer's Therapeutics Market insights The global alzheimer’s therapeutics market size was valued at USD 4.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.99% from 2023 to 2030. The rising prevalence of Alzheimer’s Disease (AD) and approval of disease-modifying therapies are expected to fuel market growth. According to the NCBI, in 2021, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, which is estimated to increase to around 13.8 million by 2060. Women are more prone to be diagnosed with Alzheimer’s disease than men due to the longer life expectancy of women. Moreover, Alzheimer’s disease is becoming the most common cause of death in neurodegenerative diseases and a common cause of physical disability that require immediate treatment. North America dominated the market with a share of over 40.79% in 2022 and is anticipated to grow at a significant rate over the forecast period. The growing research for the treatment of Alzheimer’s is propelling the market growth. In June 2021, Eisai Co., Ltd. and Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating Alzheimer’s disease, was granted the Breakthrough Therapy designation by the U.S. FDA. Moreover, the increasing government initiatives and funding are expected to boost the growth of the market. The Asia Pacific region is expected to emerge as the fastest-growing region over the forecast period owing to increasing awareness among people and the increasing research activities to develop novel drugs to treat AD. In 2022, there are around 487,500 Australians living with dementia and this number is expected to increase to 1.1 million by 2058. Dementia is the second leading cause of death in Australia. Order your copy of the Free Sample of “Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research Neurodegenerative Disease Therapeutics Market – Global Industry Segmentation Neurodegenerative Disease Therapeutics Industry, by Drug Class • Parkinson’s Disease Treatment • Alzheimer’s Therapeutics Neurodegenerative Disease Therapeutics Industry, By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • E-commerce Neurodegenerative Disease Therapeutics Industry, By Region • North America o U.S. o Canada • Europe o UK o Germany o France o Italy o Spain o Russia o Denmark o Norway o Sweden o Rest of Europe • APAC o China o Japan o India o South Korea o Australia o Singapore o Thailand o Rest of APAC • Latin America o Brazil o Mexico o Argentina o Rest of Latin America • MEA o South Africa o Saudi Arabia o UAE o Kuwait o Rest of MEA Go through the table of content of Neurodegenerative Disease Therapeutics Industry Data Book to get a better understanding of the Coverage & Scope of the study. Neurodegenerative Disease Therapeutics Industry Data Book Competitive Landscape Competitive rivalry in this market is likely to be high due to increasing number of mergers, acquisitions, and partnerships undertaken by major players globally. Many established and clinical-stage pharmaceutical companies are involved in the development of novel therapies & drugs to target people with unmet clinical needs. Key players operating in the Neurodegenerative Disease Therapeutics industry are – • Eisai Co., Ltd. • AbbVie Inc. (Allergan Plc.) • Merck & Co., Inc. • Adamas Pharmaceuticals, Inc. • Novartis AG,H. Lundbeck A/S • Cerevel Therapeutics • Biogen • Daiichi Sankyo Company, Limited • F. Hoffmann La Roche Ltd. • TauRx Pharmaceuticals Ltd. • Johnson & Johnson Services, Inc. • AC Immune • Teva Pharmaceutical Industries Ltd. • GlaxoSmithKline plc. (GSK). About Grand View Research Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead. Check out more Industry Data Books, published by Grand View Research
0 Comments
Magnetic Resonance Imaging Scanners and Accessories Industry Data Book Covers Magnetic Resonance Imaging, MRI Coils & Motion Tracking Systems Market. Grand View Research’s magnetic resonance imaging scanners and accessories industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research. Magnetic Resonance Imaging Market Insights The global magnetic resonance imaging (MRI) market size was valued at USD 5.26 billion in 2022 and is anticipated to grow at a CAGR of 6.8% over the forecast period. MRI is an efficient diagnostic machine for identifying diseases related to spine lesions, tumors, and stroke impacting the area of blood vessels and brain. The increasing prevalence of these diseases is expected to play an important role in the market growth. For instance, as per the International Agency for Research on Cancer, in 2020, 19,292,789 new cancer cases were recorded globally. In addition to this the growing demand for quick and effective diagnostic procedures is expected to contribute towards the adoption of MRI machines. North America dominated the global market by capturing over 37% of the global MRI market in 2021. Increasing incidence of chronic diseases in this region, which includes breast cancer, cardiovascular disorders, and neurological diseases is creating a demand for imaging analysis. The region is expected to maintain its dominance throughout the forecast period. Technological innovations coupled with the growing incidence of chronic conditions is anticipated to spur the growth of MRI during the forecast period. MRI Coils Market Insights The global magnetic resonance imaging coils market size was valued at USD 7.98 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. The market is being driven by several factors, including increasing demand for diagnostic imaging procedures, technological advancements in magnetic resonance imaging (MRI) coil design, and the rising prevalence of chronic diseases including neurological disorders, cancer, and cardiovascular diseases. As per the WHO estimates, cardiovascular diseases are a leading cause of death, taking 17.9 million lives each year. This, in turn, is anticipated to propel the growth of enhanced imaging diagnostics, thus, fueling the growth of the industry. North America dominated the market globally and held the highest revenue share of 27.6% in 2022. Technological advancements have led to the development of faster and more powerful machines that produce higher-quality images, which has increased the demand for MRI in the diagnosis and treatment of various medical conditions. The prevalence of chronic diseases is also increasing, leading to a higher demand for imaging services. Europe also held a significant share in the market this can be attributed to factors such as an increase in the prevalence of chronic disorders, and rapid adoption of advanced technologies, According to the European heart network, each year, cardiovascular diseases cause around 3.9 million deaths in Europe which are fueling the demand of MRI Coils. Order your copy of the Free Sample of “Magnetic Resonance Imaging Scanners and Accessories Industry Data Book - Magnetic Resonance Imaging, MRI Coils & Motion Tracking Systems Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research Motion Tracking Systems Market Insights The global MRI motion tracking systems market size was valued at USD 2.7 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 20.76% from 2022 to 2030. MRI is an efficient tool to detect aneurysms, tumors, and abnormalities in the brain and body. As per OECD, in 2020 the number of MRI units installed in the U.S. was 34.54 per million population. However, it is the growing need of the hour to develop a system that improves the stability of the image captured by MRI and reduces unnecessary rescans. Scans conducted for patients needing sedation such as pediatrics and geriatric patients with involuntary motions, often record motion artifacts, creating unclear diagnostic scans. Hence, motion tracking systems, are used to tackle such issues. North America dominated the global market by capturing over 58.3% of the revenue share in 2021. Increased adoption of MRI scans over other diagnostic modalities, high healthcare GDP, stringent diagnostic regulation, and the presence of numerous research institutes working to develop more effective systems. The APAC region accounts for a higher CAGR of 40.8% in the forecast period. This high-growth region holds the potential to develop local systems at a minimized cost in the future and increased contracts to contract research manufacturers from manufacturers of developed nations. Latin America and the Middle East and Africa markets generated no revenue from 2020 to 2021. However, it is said to improve by 2022 as local players would enter the market. The APAC region accounts for a higher CAGR of 40.8% in the forecast period. This high-growth region holds the potential to develop local systems at a minimized cost in the future and increased contracts to contract research manufacturers from manufacturers of developed nations. Latin America and the Middle East and Africa markets generated no revenue from 2020 to 2021. However, it is said to improve by 2022 as local players would enter the market. Go through the table of content of Customer Relationship Management Industry Data Book to get a better understanding of the Coverage & Scope of the study. Magnetic Resonance Imaging Scanners and Accessories Industry Data Book Competitive Landscape The high price is one of the most impeding factors for the sales of these systems. The major players are focusing on minimizing the prices for medium-strength MRI systems using various methods. Technological advancements in manufacturing and the high influx of these systems in the market is expected to bring the prices down in the upcoming years. Key players operating in the Magnetic Resonance Imaging Scanners and Accessories Industry are – • GE Healthcare • Siemens Healthineers • Toshiba Corporation • Aurora Imaging Technologies, Inc. • Koninklijke Philips N.V. • Esaote SPA • Sanrad Medical Systems Pvt ltd • Fujifilm • MR Instruments, Inc. • RAPID MR International, LLC • ScanMed • Canon Medical Systems Corporation • Hologic Inc. • Bruker • TracInnovations • Kineticor • Metria Innovations Stem cells industry data book covers human embryonic stem cells, induced pluripotent stem cells production, mesenchymal stem cells, stem cells and cancer stem cells market. Grand View Research’s Stem Cells Industry databook is a collection of market sizing & forecasts insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the databook, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in five reports and one sector report overview. Human Embryonic Stem Cells Market Insights The human embryonic stem cells market was valued at USD 1.10 Billion in 2022 with a CAGR of 10.6% during 2023-2030. These are the pluripotent cells that possess the ability to get differentiated into all germ layers. Rising demand owing to the increasing incidence of genetic disorders is anticipated to boost growth. Research carried out in order to utilize them for disease eradication is expected to support projected growth. Controlled differentiation that can be achieved in tissue committed cells through the co-culturing with basic fibroblast growth factor is expected to induce growth. Variation in the policies across the globe is expected to impact the global human embryonic stem cell market development. North America dominated the market with respect to revenue generation as a result of the presence of several prominent entities incorporated in the U.S. As hESC research is permitted in Belgium, Finland, UK, Denmark, Sweden, and the Netherlands, Europe is estimated to follow North America in revenue generation. Moreover, the government of Asian countries is supportive of hESC research thus boosting growth in this region. Induced Pluripotent Stem Cells Market Insights The induced pluripotent stem cells production market was valued at USD 1.36 Billion in 2022 with a CAGR of 9.3% during 2023-2030. The potential of stem cell-based therapies, increasing capital investments for stem cell-based research, the growing incidence of cancer, and multiple advantages of induced pluripotent stem cells (iPSCs) over Embryonic Stem Cells (ESCs) are driving the market growth significantly. The increase in research activities during the COVID-19 pandemic also boosted iPSCs-based research activities. The continuous strive by scientists to develop novel treatment and therapies to manage the SARS CoV-2 infection have driven the demand for iPSCs as research tools. In addition, as induced pluripotent stem cells are capable of generating physiologically similar organ models or organoids, these cells can be used to understand the pathophysiology of the virus infection in humans. North America held the largest revenue share of 59.3% in 2021. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace. In addition, North America is also observing the highest number of clinical trials for iPSCs. Currently, there are more than 58 clinical trials that are underway in this region. Moreover, institutes like NIH, California Institute for Regenerative Medicine (CIRM), National Institute of Neurological Disorders and Stroke (NINDS), and many more support induced pluripotent stem cells (iPSCs) related research activities. Order your copy of the Free Sample of “Stem Cells Industry Data Book - Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research Mesenchymal Stem Cells Market insights The mesenchymal stem cells market was valued at USD 3.02 Billion in 2022 with a CAGR of 11.4% during 2023-2030. An increase in prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders coupled with rising implication of stem cells in management of these chronic conditions are anticipated to drive global mesenchymal stem cell market. In addition, increasing popularity of regenerative medicine and surge in R&D activities by biopharmaceutical companies to develop novel therapies by using mesenchymal stem cells is another factor propelling market growth forward. North America dominated the market and accounted for the largest revenue share of 44.28% in 2022. A substantial number of clinical trials are underway to assess the efficacy and safety of mesenchymal stem cells as a viable treatment, for several life-threatening diseases in the U.S. Furthermore, a significant number of major companies that are engaged in the supply and commercialization of MSCs are headquartered in the North America. In addition, supportive government legislation, rising demand for innovative therapeutics, and increasing efforts from market participants to develop advanced mesenchymal stem cell therapies for managing chronic disorders. These factors have contributed to the dominance of the region in the market. Cancer Stem Cells Market Insights Cancer stem cells market was valued at USD 2.59 Billion in 2022 with a CAGR of 12.1% during 2023-2030. The market is expected to expand at a CAGR of 9.98% during the forecast period. Currently, oncology therapeutics has entered a new era with conventional therapies such as radiotherapy, chemotherapy, & surgeries on one side and stem cell therapies on another side. North America was the leading revenue contributor to the cancer stem cells market in 2016 due to the presence of a substantial number of organizations engaged in conducting R&D activities related to stem cell therapy. There are several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, which offer stem cell transplant therapies. Asia Pacific is expected to be a promising region in the arena owing to the presence of several organizations in the region that focus on R&D of stem cells. Moreover, funding agencies are providing grants to research communities to accelerate their scientific research on cancer stem cells in Asian countries. Stem Cells Market Insights The stem cells market was valued at USD 13.26 Billion in 2022 with a CAGR of 11.4% during 2023-2030. The growing development of precision medicine, increase in the number of cell therapy production facilities and rising number of clinical trials are expected to be major driving factors of the market. Recent advances in the stem cells therapeutics and the tissue engineering hold the potential to draw the attention for treatment of several diseases. Furthermore, increasing demand for stem cells banking and rise in research activities pertaining to stem cells production, storage, and characterization are also expected to fuel the revenue growth for the market. Technological improvements in the parent and ancillary market for stem cells usage are some of the other factors that reinforce the expected growth in demand for stem cells over the forecast period. North America accounted for the largest revenue share of 43.56% in 2022. Presence of innovators and key market players has resulted into higher penetration of market products in the region. North America leads the market owing to strong biotechnology industry, presence of key players, extensive R&D and promotion of personalized medicines. The region accounts for the highest revenue share. Moreover, growth in this region can be further attributed to rising government initiative for promoting stem cell therapies. For instance, in March 2020, the government of Canada invested around USD 7 million in regenerative medicine and stem cell research. It will support 9 transnational projects and 4 clinical trials in the country for growing regenerative medicine sector. Go through the table of content of Stem Cells Industry Data Book to get a better understanding of the Coverage & Scope of the study. Stem Cells Industry Data Book Competitive Landscape Competitive rivalry in the stem cell industry is high due to the presence of a large number of both well-established players and small- to mid-sized companies as well as CROs in the market space. Key players operating in the stem cells industry are – • STEMCELL Technologies Inc. • Advanced Cell Technology Inc. • Cellular Engineering Technologies Inc. • CellGenix GmbH • Angel Biotechnology • PromoCell GmbH • Kite Pharma • Lonza • Cellartis AB • Celgene Corporation • Brainstorm Cell Therapeutics • Osiris Therapeutics • Genea Biocells • Waisman Biomanufacturing • Bioheart Inc. • Tigenix • Caladrius Biosciences • Gamida Cell |
Archives
December 2023
Categories |